The evolving role of lenalidomide in non-Hodgkin lymphoma

References

• NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's lymphomas. Vol. Version 1.2016; v1.2016. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf [last accessed 8 Jan 2016].
   Google Scholar
• List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–1465.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357:2123–2132.
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357:2133–2142.
   PubMed Web of Science ®Google Scholar
• Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31:3688–3695.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4952–4957.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol. 2009;27:5404–5409.
   PubMed Web of Science ®Google Scholar
• Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007;67:746–755.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118:4771–4779.
   PubMed Web of Science ®Google Scholar
• Zhang LH, Kosek J, Wang M, et al. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol. 2013;160:487–502.
   PubMed Web of Science ®Google Scholar
• Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326–2335.
   PubMed Web of Science ®Google Scholar
• Fecteau JF, Corral LG, Ghia EM, et al. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood. 2014;124:1637–1644.
   PubMed Web of Science ®Google Scholar
• Chamberlain PP, Lopez-Girona A, Miller K, et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014;21:803–809.
   PubMed Web of Science ®Google Scholar
• Fischer ES, Bohm K, Lydeard JR, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014;512:49–53.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33:2803–2811.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22:1622–1627.
   PubMed Web of Science ®Google Scholar
• Trneny M, Lamy T, Walewski J, et al. Phase II randomized, multicenter study of lenalidomide vs best investigator’s choice in relapsed/refractory mantle cell lymphoma: results of the MCL-002 (SPRINT) study. Blood (Suppl) 2014;124:Abstract 626.
   Google Scholar
• Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol. 2012;159:154–163.
   PubMed Web of Science ®Google Scholar
• Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012;13:716–723.
   PubMed Web of Science ®Google Scholar
• Chong EA, Ahmadi T, Aqui N, et al. Combination of lenalidomide and rituximab overcomes rituximab-resistance in patients with indolent B-cell and mantle cell lymphomas. Clin Cancer Res. 2015;21:1835–1842.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Shah BD, et al. Sustained remission with the combination biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma: a multicenter phase II study report. Blood (Suppl) 2014;124:Abstract 625.
   Google Scholar
• Jerkeman M, Albertsson-Lindblad A, Kolstad A, et al. Lenalidomide, bendamustine, and rituximab as first-line therapy for patients >65 years with mantle cell lymphoma: preliminary results from the Nordic Lymphoma Group MCL4 (LENA-BERIT) phase I–II trial. Blood. 2013;122:Abstract 4377.
   Google Scholar
• Jerkeman M, Kolstad A, Laurell A, et al. Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: results from the phase I portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) trial. Blood 2011;118:Abstract 2700.
   Google Scholar
• Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145:344–349.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Vose JM, Czuczman MS, et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol. 2013;24:2892–2897.
   PubMed Web of Science ®Google Scholar
• Goy A, Kalayoglu Besisik S, Drach J, et al. Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial. Br J Haematol. 2015;170:496–503.
   PubMed Web of Science ®Google Scholar
• REVLIMID (lenalidomide) prescribing information. Summit (NJ): Celgene Corporation; 2015.
   Google Scholar
• Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005;11:5984–5992.
   PubMed Web of Science ®Google Scholar
• Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008;140:36–45.
   PubMed Web of Science ®Google Scholar
• Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009;84:553–559.
   PubMed Web of Science ®Google Scholar
• Smith SM, Pitcher B, Jung SH, et al. Unexpected and serious toxicity observed with combined idelalisib, lenalidomide and rituximab in relapsed/refractory B cell lymphomas: Alliance A051201 and A051202. Blood (Suppl). 2014;124:Abstract 3091.
   Google Scholar
• Hitz F, Fischer N, Pabst T, et al. Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. Ann Hematol. 2013;92:1033–1040.
   PubMed Web of Science ®Google Scholar
• Tuscano JM, Dutia M, Chee K, et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014;165:375–381.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Jung SH, Johnson J, et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol. 2015;33:3635–3640.
   PubMed Web of Science ®Google Scholar
• Martin P, Jung S, Johnson J, et al. CALGB 50803(ALLIANCE): a phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. Hematol Oncol (Suppl). 2013;31:117Abstract 063.
   PubMed Web of Science ®Google Scholar
• Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15:1311–1318.
   PubMed Web of Science ®Google Scholar
• Wang M, Fowler N, Wagner-Bartak N, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27:1902–1909.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Pellegrini C, Derenzini E, et al. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. Hematol Oncol. 2013;31:223–224.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Pellegrini C, Gandolfi L, et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk. 2011;11:462–466.
   PubMed Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Salles G, et al. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia. 2013;27:252–255.
   PubMed Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Casasnovas O, et al. Lenalidomide in combination with R-CHOP (R2-CHOP) in patients with high burden follicular lymphoma: phase 2 study. Blood (Suppl). 2013;122:Abstract 248.
   Google Scholar
• Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol. 2015;33:251–257.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Chiappella A, Franceschetti S, et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol. 2014;15:730–737.
   PubMed Web of Science ®Google Scholar
• Martin P, Jung SH, Johnson JL, et al. CALGB 50803 (Alliance): a phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. J Clin Oncol (Suppl). 2014;32:Abstract 8521.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Czuczman M, Vose J, Zinzani PL, et al. Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: results from an international study (NHL-003). J Clin Oncol (Suppl). 2009;27:Abstract e19504.
   Web of Science ®Google Scholar
• Czuczman M, Vose J, Zinzani PL, et al. Lenalidomide monotherapy is clinically active in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL): a pooled analysis of data from phase II studies (NHL-002/003). Haematologica (Suppl). 2010;95:239. (Abstract 574).
   Web of Science ®Google Scholar
• Czuczman MS, Davies A, Linton KM, et al. A phase 2/3 multicenter, randomized study comparing the efficacy and safety of lenalidomide versus investigator’s choice in relapsed/refractory DLBCL. Blood (Suppl). 2014;124:Abstract 628.
   Google Scholar
• Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117:5058–5066.
   PubMed Web of Science ®Google Scholar
• Keifer JA, Guttridge DC, Ashburner BP, et al., Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 2001;276:22382–22387.
   PubMed Web of Science ®Google Scholar
• Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861–1874.
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011;118:5119–5125.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Pellegrini C, Broccoli A, et al. Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma. 2011;52:1585–1588.
   PubMed Web of Science ®Google Scholar
• Yang Y, Shaffer AL, 3rd, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21:723–737.
   PubMed Web of Science ®Google Scholar
• Imbruvica (ibrutinib) prescribing information. Sunnyvale (CA): Pharmacyclics, Inc.; January 2015.
   Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370:1008–1018.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516.
   PubMed Web of Science ®Google Scholar
• Zydelig (idelalisib) prescribing information. Foster City (CA): Gilead Sciences, Inc.; July 2014.
   Google Scholar